New cream tested for Hard-to-Treat skin condition in transplant patients
NCT ID NCT03954236
Summary
This study is testing whether a new prescription cream (ruxolitinib 1.5%) is safer and more effective than standard moisturizers for treating a specific type of skin inflammation that can occur after a stem cell transplant. About 24 participants will apply the test cream to one side of their body and a moisturizer to the other side for 28 days to compare results. The goal is to see if the new cream can better reduce the affected skin area and improve its appearance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SCLEROTIC CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.